Bone Biologics Corporation

NasdaqCM:BBLG Stock Report

Market Cap: US$1.5m

Bone Biologics Past Earnings Performance

Past criteria checks 0/6

Bone Biologics's earnings have been declining at an average annual rate of -15.9%, while the Biotechs industry saw earnings growing at 34.1% annually.

Key information

-15.91%

Earnings growth rate

111.32%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth raten/a
Return on equity-73.66%
Net Marginn/a
Last Earnings Update30 Jun 2026

Recent past performance updates

No updates

Recent updates

Analysis Article • Jun 07

Companies Like Bone Biologics (NASDAQ:BBLG) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 07

Bone Biologics prices $5.1M underwritten public offering

Orthobiologic products company Bone Biologics (NASDAQ:BBLG) priced an underwritten public offering of 3.8M units of securities at $1.35 per unit. The total gross proceeds stood at $5.1M, before deducting underwriting discounts and commissions and other estimated offering expenses. Each unit consists of one share, one series A warrant to purchase one share at an exercise price equal to $1.62 per share, one series B warrant to purchase one share at an exercise price equal to $1.35 per share and one series C warrant to purchase one share at an exercise price equal to $2.16 per share. The shares and the warrants are immediately separable and will be issued separately, but will be purchased together in this offering. The warrants expire five years from the date of issuance. Additionally, the underwriters are granted a 45-day option to purchase up to 566,666 additional shares and/or 566,666 additional warrants. The offering is expected to close on or about Oct. 11. BBLG shares were trading -26.73% pre-market. Source: Press Release
Analysis Article • Mar 18

We're Not Very Worried About Bone Biologics' (NASDAQ:BBLG) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Revenue & Expenses Breakdown

How Bone Biologics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:BBLG Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 260-321
31 Mar 260-321
31 Dec 250-321
30 Sep 250-422
30 Jun 250-722
31 Mar 250-722
31 Dec 240-722
30 Sep 240-721
30 Jun 240-523
31 Mar 240-635
31 Dec 230-937
30 Sep 230-727
30 Jun 230-626
31 Mar 230-524
31 Dec 220-122
30 Sep 220-321
30 Jun 220-220
31 Mar 220-220
31 Dec 210-210
30 Sep 210-210
30 Jun 210-210
31 Mar 210-200
31 Dec 200-200
30 Sep 200-200
30 Jun 200-210
31 Mar 200-311
31 Dec 190-311
30 Sep 190-422
30 Jun 190-421
31 Mar 190-430
31 Dec 180-430
30 Sep 180-630
30 Jun 180-831
31 Mar 180-64-2
31 Dec 170-74-1
30 Sep 170-1470
30 Jun 170-1673
31 Mar 170-2288
31 Dec 160-26912
30 Sep 160-241012
30 Jun 160-231110
31 Mar 160-1998
31 Dec 150-1484

Quality Earnings: BBLG is currently unprofitable.

Growing Profit Margin: BBLG is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BBLG is unprofitable, and losses have increased over the past 5 years at a rate of 15.9% per year.

Accelerating Growth: Unable to compare BBLG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BBLG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (64.6%).

Return on Equity

High ROE: BBLG has a negative Return on Equity (-73.66%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/14 08:56
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bone Biologics Corporation is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bradley SorensenZacks Small-Cap Research